January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
November 2024 in “Rheumatology Advances in Practice” Rheumatology clinics should always provide preconception counseling for women on DMARDs.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
42 citations
,
April 2011 in “Annals of Pharmacotherapy” Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
64 citations
,
May 2000 in “International Journal of Dermatology” Thalidomide improved lupus symptoms but caused nerve damage in some patients.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
2 citations
,
January 2012 in “PubMed” Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
116 citations
,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.